WO2012054824A3 - Prognostic biomarkers in patients with ovarian cancer - Google Patents

Prognostic biomarkers in patients with ovarian cancer Download PDF

Info

Publication number
WO2012054824A3
WO2012054824A3 PCT/US2011/057271 US2011057271W WO2012054824A3 WO 2012054824 A3 WO2012054824 A3 WO 2012054824A3 US 2011057271 W US2011057271 W US 2011057271W WO 2012054824 A3 WO2012054824 A3 WO 2012054824A3
Authority
WO
WIPO (PCT)
Prior art keywords
ovarian cancer
patients
prognostic biomarkers
methods
biological
Prior art date
Application number
PCT/US2011/057271
Other languages
French (fr)
Other versions
WO2012054824A2 (en
Inventor
Estrid Hogdall
Eric T. Fung
Ib Jarle Christensen
Claus Hogdall
Original Assignee
Vermillion, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vermillion, Inc. filed Critical Vermillion, Inc.
Priority to CA2818593A priority Critical patent/CA2818593A1/en
Priority to AU2011316844A priority patent/AU2011316844A1/en
Priority to JP2013535113A priority patent/JP2013541716A/en
Priority to EP11835211.1A priority patent/EP2630498A4/en
Publication of WO2012054824A2 publication Critical patent/WO2012054824A2/en
Publication of WO2012054824A3 publication Critical patent/WO2012054824A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44756—Apparatus specially adapted therefor
    • G01N27/44773—Multi-stage electrophoresis, e.g. two-dimensional electrophoresis
    • G01N27/44778—Multi-stage electrophoresis, e.g. two-dimensional electrophoresis on a common gel carrier, i.e. 2D gel electrophoresis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Abstract

The present invention provides methods for assessing an ovarian cancer patient's survival status. Also, methods for evaluating the ovarian cancer state of a patient are described herein. These methods involve the detection, analysis, and classification of biological patterns in biological samples. The biological patterns are obtained using, for example, mass spectrometry systems and other techniques.
PCT/US2011/057271 2010-10-22 2011-10-21 Prognostic biomarkers in patients with ovarian cancer WO2012054824A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA2818593A CA2818593A1 (en) 2010-10-22 2011-10-21 Prognostic biomarkers in patients with ovarian cancer
AU2011316844A AU2011316844A1 (en) 2010-10-22 2011-10-21 Prognostic biomarkers in patients with ovarian cancer
JP2013535113A JP2013541716A (en) 2010-10-22 2011-10-21 Prognostic biomarkers in patients with ovarian cancer
EP11835211.1A EP2630498A4 (en) 2010-10-22 2011-10-21 Prognostic biomarkers in patients with ovarian cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40604410P 2010-10-22 2010-10-22
US61/406,044 2010-10-22

Publications (2)

Publication Number Publication Date
WO2012054824A2 WO2012054824A2 (en) 2012-04-26
WO2012054824A3 true WO2012054824A3 (en) 2012-07-19

Family

ID=45975910

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/057271 WO2012054824A2 (en) 2010-10-22 2011-10-21 Prognostic biomarkers in patients with ovarian cancer

Country Status (5)

Country Link
EP (1) EP2630498A4 (en)
JP (2) JP2013541716A (en)
AU (1) AU2011316844A1 (en)
CA (1) CA2818593A1 (en)
WO (1) WO2012054824A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4286853A3 (en) * 2013-05-10 2024-03-06 Johns Hopkins University Compositions for ovarian cancer assessment having improved specificity
JP6019254B2 (en) 2014-04-23 2016-11-02 株式会社ニチレイバイオサイエンス Target marker detection combination
EP3435379A1 (en) * 2017-07-27 2019-01-30 Roche Diagnostics GmbH Augmenting measurement values of biological samples
WO2019088709A2 (en) * 2017-10-31 2019-05-09 국립암센터 Information providing method for predicting ovarian cancer prognosis by using nc886 gene
JP7272627B2 (en) * 2019-01-24 2023-05-12 公立大学法人和歌山県立医科大学 Biomarkers for evaluation of ovarian tumors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059013A1 (en) * 2002-08-06 2005-03-17 The Johns Hopkins University Use of biomarkers for detecting ovarian cancer
US20090004687A1 (en) * 2007-06-29 2009-01-01 Mansfield Brian C Predictive markers for ovarian cancer
US20100055690A1 (en) * 2006-10-13 2010-03-04 Vermillion, Inc. Prognostic biomarkers in patients with ovarian cancer
US20100068724A1 (en) * 2005-03-11 2010-03-18 Vermilllion, Inc. Biomaker for ovarian and endometrial cancer: hepcidin
US20100068818A1 (en) * 2006-10-04 2010-03-18 The Johns Hopkins University Algorithms for multivariant models to combine a panel of biomarkers for assessing the risk of developing ovarian cancer
US20100081151A1 (en) * 2004-07-14 2010-04-01 The Regents Of The University Of California Biomarkers for early detection of ovarian cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2993474B1 (en) * 2005-06-24 2019-06-12 Vermillion, Inc. Biomarkers for ovarian cancer: beta-2 microglobulin
JP5391400B2 (en) * 2007-10-01 2014-01-15 公益財団法人ヒューマンサイエンス振興財団 Method for assisting detection of pancreatic cancer using copy number or expression level of α-actinin-4 gene as an index and kit for diagnosis
EP2220506B1 (en) * 2007-10-29 2013-10-02 Vermillion, Inc. Biomarkers for the detection of early stage ovarian cancer
WO2010091763A1 (en) * 2009-02-16 2010-08-19 Atlas Antibodies Ab Rbm3 as a marker for malignant melanoma prognosis

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059013A1 (en) * 2002-08-06 2005-03-17 The Johns Hopkins University Use of biomarkers for detecting ovarian cancer
US20100081151A1 (en) * 2004-07-14 2010-04-01 The Regents Of The University Of California Biomarkers for early detection of ovarian cancer
US20100068724A1 (en) * 2005-03-11 2010-03-18 Vermilllion, Inc. Biomaker for ovarian and endometrial cancer: hepcidin
US20100068818A1 (en) * 2006-10-04 2010-03-18 The Johns Hopkins University Algorithms for multivariant models to combine a panel of biomarkers for assessing the risk of developing ovarian cancer
US20100055690A1 (en) * 2006-10-13 2010-03-04 Vermillion, Inc. Prognostic biomarkers in patients with ovarian cancer
US20090004687A1 (en) * 2007-06-29 2009-01-01 Mansfield Brian C Predictive markers for ovarian cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2630498A4 *

Also Published As

Publication number Publication date
CA2818593A1 (en) 2012-04-26
AU2011316844A1 (en) 2013-06-06
JP2013541716A (en) 2013-11-14
JP2016212116A (en) 2016-12-15
EP2630498A2 (en) 2013-08-28
EP2630498A4 (en) 2014-10-01
WO2012054824A2 (en) 2012-04-26

Similar Documents

Publication Publication Date Title
WO2008048508A3 (en) Prognostic biomarkers in patients with ovarian cancer
WO2006108087A3 (en) Devices and methods for enrichment and alteration of circulating tumor cells and other particles
IL251791A0 (en) Biomarker for ovarian cancer: ctap3-related proteins
WO2007079229A3 (en) Devices and methods for enrichment and alteration of circulating tumor cells and other particles
WO2012021795A3 (en) Pancreatic cancer biomarkers and uses thereof
WO2012177945A3 (en) Diagnostic methods for eosinophilic esophagitis
WO2008039946A3 (en) Integrated meter for analyzing biological samples
WO2009134944A3 (en) Methods of determining the health status of an individual
WO2008109878A3 (en) Testing device
WO2009074276A3 (en) Marker panel for colorectal cancer
EP3029153A3 (en) Mesothelioma biomarkers and uses thereof
WO2010056945A3 (en) Methods and systems for tissue processing and imaging
WO2009055052A3 (en) Improved methods and devices for cellular analysis
WO2011088014A3 (en) Systems and methods for counting cells and biomolecules
MX355416B (en) Lung cancer biomarkers and uses thereof.
WO2010027903A8 (en) Lung cancer diagnosis
WO2007002527A3 (en) BIOMARKERS FOR OVARIAN CANCER: β-2 MICROGLOBULIN
WO2006034032A3 (en) Biomarkers for breast cancer
BRPI0606685A2 (en) gitr antibodies for diagnosis of nsclc
WO2007114986A3 (en) Cooperative probes and methods of using them
EP2569635A4 (en) Methods for diagnosing and treating encephalitis or epilepsy
WO2012054824A3 (en) Prognostic biomarkers in patients with ovarian cancer
WO2009099905A3 (en) Molecular signatures and biomarkers associated with melanoma and methods of use thereof
WO2006128082A3 (en) Biomarkers for breast cancer
WO2011137388A3 (en) Identification and use of biomarkers for detection and quantification of the level of radiation exposure in a biological sample

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11835211

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2013535113

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2818593

Country of ref document: CA

REEP Request for entry into the european phase

Ref document number: 2011835211

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011835211

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2011316844

Country of ref document: AU

Date of ref document: 20111021

Kind code of ref document: A